A reading of the reports suggests that there is no standard practice for reporting political contributions and it is left to the company's discretion to report them as they find fit. Illustration:......
Ahmedabad-based Zydus Cadila, Bharat Biotech’s intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.......
The index is currently trading at 149 per cent of its historical P/B valuation, surpassing its previous peak of 125 per cent made in 2020-21. Illustration: Dominic Xavier/Rediff.com Indian......
Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those gains......
An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India’s pharmaceutical companies during the first quarter of this financial......
Healthcare stocks have outperformed the benchmark indices since the start of the current financial year. Illustration: Uttam Ghosh/Rediff.com The BSE Healthcare Index is up 19 per cent as compared......
Drug shortages in the US are at an all-time high, and price erosion has stabilised, which could benefit Indian pharmaceutical (pharma) companies with a US focus, according to analysts. Image used......